首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Combined peritoneal dialysis and hemodialysis: our experience compared to others.
【24h】

Combined peritoneal dialysis and hemodialysis: our experience compared to others.

机译:腹膜透析和血液透析联合治疗:我们的经验与其他人相比。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine the clinical experience of using combined-modality [simultaneous hemodialysis (HD) and peritoneal dialysis (PD)] treatment in patients with end-stage renal disease. DESIGN: We reviewed data on 4 patients from our center that were treated with "combined-mode therapy." We then conducted a retrospective survey by sending questionnaires to nephrologists in the US and Canada by mail and by posting the survey on the Internet. Data queried included number of patients on combined modality, solute clearances, albumin levels pre and post combined therapy, reasons for using combined therapy, duration and success of combined therapy, and reimbursement issues. SETTING AND PARTICIPANTS: Ours is a tertiary-care center. Patients that were not doing well on PD alone were put on combined modality of treatment between 1992 and 1998. MAIN OUTCOME MEASURES: Clinical improvement in the indication for which the participant was started on combined modality. RESULTS: In response to the survey, data on 27 patients were collected. These data were combined with data on 4 patients from our unit that had previously been treated with combined HD and PD. Most patients were reported to have more than one clinical reason for changing from PD to combined therapy. The main clinical reason for offering combined treatments was inadequate solute clearance (34%), followed by ultrafiltration problems (16%) and neuropathy (11%). Mean duration of time followed on combined treatment was 8.5 +/- 0.12 months. Most patients tolerated combined treatment well and were reported to show improvement in the clinical reasons for which they needed the combined modality. Dual access and reimbursement issues were not a problem. There was no single method used for calculating total (HD, PD, and residual renal) solute clearance. No universal total solute clearance goal was reported. CONCLUSION: Hemodialysis and PD are not mutually exclusive. They can be used in combination to achieve targeted solute clearances, to improve certain clinical conditions, and to control volume and blood pressure in a subset of patients. Further evaluation is needed to better establish the long-term outcomes of using combined modality. Total solute clearance goals and methods for determining total solute clearance need to be standardized.
机译:目的:确定在晚期肾病患者中使用联合方式[同时血液透析(HD)和腹膜透析(PD)]治疗的临床经验。设计:我们审查了来自我们中心的4例接受“联合模式疗法”治疗的患者的数据。然后,我们通过邮寄问卷给美国和加拿大的肾脏病医生并在互联网上发布了调查问卷,进行了回顾性调查。查询的数据包括:联合治疗方式,溶质清除率,联合治疗前后的白蛋白水平,使用联合治疗的原因,联合治疗的持续时间和成功率以及报销问题的患者人数。地点和参加者:我们是一家三级护理中心。仅在PD方面表现不佳的患者在1992年至1998年间接受了联合治疗。主要观察指标:参与者开始采用联合治疗的适应症的临床改善。结果:根据调查,收集了27例患者的数据。这些数据与来自我们单位的4例患者的数据进行了合并,这些患者之前曾接受过HD和PD的联合治疗。据报道,大多数患者有多种原因导致从PD转为联合治疗。提供联合治疗的主要临床原因是溶质清除率不足(34%),其次是超滤问题(16%)和神经病(11%)。联合治疗后的平均持续时间为8.5 +/- 0.12个月。大多数患者对联合治疗的耐受性良好,据报道他们需要联合治疗的临床原因有所改善。双重访问和报销问题不是问题。没有用于计算总(HD,PD和残余肾脏)溶质清除率的单一方法。没有普遍的总溶质清除目标的报道。结论:血液透析和局部放电不是相互排斥的。它们可以组合使用以实现目标溶质清除率,改善某些临床状况并控制部分患者的血容量和血压。需要进行进一步评估,以更好地确定使用组合方式的长期结果。总溶质清除率的目标和确定总溶质清除率的方法需要进行标准化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号